Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Farma ondernemingen’

Severe asthma patients require more support, Novartis study suggests

A new study from Novartis has indicated that patients suffering from severe asthma still do not get adequate support to mitigate the burden placed by the disease on their personal and professional lives, despite the availability of inhaled and oral treatments.

Bron: Pharmafile Meer lezen »

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of biosimilar to Humira

Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Bron: World Pharma News Meer lezen »

From pipeline to patients: Navigating treatments through the UK system

Pharmafocus spoke to Karen Lightning-Jones, Integrated Franchise Leader, Pipeline, to discuss the current UK climate for successfully developing drugs to provide to patients, covering what is needed by the next government and how Switzerland provides a model to thrive outside the EU.

Bron: Pharmafile Meer lezen »

Will AstraZeneca’s SGLT2-favoring data win the class a shot at front-line diabetes use?

Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest.

Bron: FiercePharma Meer lezen »

Bayer, J&J win second U.S. trial over Xarelto bleeding risks

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday.

Bron: Reuters Meer lezen »

AstraZeneca CEO warns of ‘substantial setback’ if new drug fails

AstraZeneca will face a “substantial setback” if its most ambitious foray into cutting edge immunotherapy falls flat, its chief executive Pascal Soriot has acknowledged. The eagerly awaited study into a new lung cancer drug is expected to produce its first results within weeks.

Bron: The Financial Times Meer lezen »

FDA Approves First Generic Version of Truvada

The Food and Drug Administration (FDA) has approved Teva’s Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200mg/300mg, the first generic version of  Gilead’s Truvada 200mg/300mg. Teva’s product was determined to be bioequivalent and therapeutically equivalent to the reference drug.

Bron: Monthly Prescribing Reference (MPR): Drug News Meer lezen »

Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials

France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol. Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.

Bron: Reuters Meer lezen »

Novartis touts new T-cell therapy data in race for FDA approval

Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Bron: Reuters Meer lezen »

Teva’s migraine drug clears another hurdle, aims for launch in 2018

Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study, setting it on course for U.S regulatory approval and launch in the second half of 2018.

Bron: Reuters Meer lezen »

« Oudere artikelen |